READDI-AC promotes the collaboration of multi-disciplinary teams from across the globe in their efforts to discover and develop new antiviral drugs.

The links below highlight some of our key partners in our efforts:

The Structural Genomics Consortium, a public-private partnership supporting READDI-AC as lead Medicinal Chemistry efforts.

JNJ/JPNV, a multinational pharmaceutical company leads READDI-AC in Medicinal Chemistry efforts for Project 4.

X-Chem, a pioneer in the field of small molecule drug discovery using DNA-encoded library (DEL) technology, medicinal chemistry and artificial intelligence (AI), serves as a part of the READDI-AC Discovery Core.

XChem, a section of Diamond Light Source focused on fragment-based screening for early drug discovery is a part of the READDI-AC Discovery Core.

Analiza, a US-based niche CRO that specializes in high-throughput physicochemical property and in-vitro ADME screening, serving as a CRO partner of the Discovery and MedChem Cores.

Chimerix, a biopharmaceutical company focused on developing and commercializing innovative antiviral drugs to address unmet medical needs, serving as a CRO partner of the Discovery and MedChem Cores.

Piramal, a CDMO business offering a comprehensive range of services across the drug lifecycle from drug discovery services and development to commercial manufacturing of drug substances and drug products, serving as a CRO partner of the Discovery and MedChem Cores.

AI-Driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium, an association of groups working with artificial intelligence and machine learning to accelerate structure-based drug discovery

Antiviral Drug Discovery (AViDD) Open Science Forum, a public venue to enable NIH-funded AViDD Centers to openly exchange and disseminate information in a pre-competitive fashion

QCRG Pandemic Response Program, an interdisciplinary program that aims to identify new direct-acting antivirals for SARS-CoV-2 and 19 other viruses.

Center for Antiviral Medicines and Pandemic Preparedness, a collaborative drug discovery network of expert scientist focused on generating a more substantial pool of antiviral drug candidates.